{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-077161","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.310658+00:00","generated_at":"2026-06-13T13:46:15.537766+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pacific Biosciences exchanges $441M of 2028 notes for new 1.375% 2030 convertible notes","bullets":["Issued $441M principal of 1.375% Convertible Senior Notes due 2030 in exchange for $441M of 1.50% 2028 Notes.","No cash proceeds; accrued interest paid on exchanged notes; $459M of 2028 Notes remain outstanding.","New notes mature Dec 15, 2030, convertible at ~46.5116 shares/$1,000 (initial conversion price ~$21.50/share).","Notes redeemable after June 20, 2028 if stock price exceeds 150% of conversion price for 20 of 30 consecutive trading days.","Transaction privately negotiated with Chimera Investment LLC under Section 4(a)(2) exemption."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-077161","json":"https://secwatch.observer/filing/0001104659-23-077161.json","markdown":"https://secwatch.observer/filing/0001104659-23-077161.md","text":"https://secwatch.observer/filing/0001104659-23-077161.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/0001104659-23-077161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/tm2320097d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:46:15.537766+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d85c51f9094bdd1119a92c38a75e6ee781031f22","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. incurred convertible notes of $441 million in aggregate principal amount with Chimera Investment LLC at 1.375% per annum maturing December 15, 2030.","evidence_excerpt":"On June 30, 2023, Pacific Biosciences of California, Inc. (the “Company”) consummated the previously announced privately negotiated exchange with Chimera Investment LLC (“Chimera”), a holder of its outstanding 1.50% Convertible Senior Notes due 2028 (the “2028 Notes”), pursuant to which the Company issued $441 million in aggregate principal amount of the Company’s 1.375% Convertible Senior Notes due 2030 (the “New Notes”) in exchange for $441 million principal amount of the 2028 Notes (the “Exchange Transaction”),","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/0001104659-23-077161-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$441 million in aggregate principal amount"},{"label":"Counterparty","value":"Chimera Investment LLC"},{"label":"Rate","value":"1.375% per annum"},{"label":"Maturity","value":"December 15, 2030"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"a80dbb85278caba2cebbb52f4b47d2f0f925b47a","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. entered into 1.375% Convertible Senior Notes due 2030 Indenture with U.S. Bank Trust Company, National Association valued at $441,000,000 aggregate principal amount of 1.375% Convertible Senior Notes due 2030 (effective 2023-06-30).","evidence_excerpt":"On June 30, 2023, Pacific Biosciences of California, Inc. (the \"Company\") consummated the previously announced privately negotiated exchange with Chimera Investment LLC (\"Chimera\"), a holder of its outstanding 1.50% Convertible Senior Notes due 2028 (the \"2028 Notes\"), pursuant to which the Company issued $441 million in aggregate principal amount of the Company's 1.375% Convertible Senior Notes due 2030 (the \"New Notes\") in exchange for $441 million principal amount of the 2028 Notes (the \"Exchange Transaction\"), pursuant to exemptions from registration under the Securities Act of 1933, as amended, and the rules and regulations thereunder.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000110465923077161/0001104659-23-077161-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"U.S. Bank Trust Company, National Association"},{"label":"Value","value":"$441,000,000 aggregate principal amount of 1.375% Convertible Senior Notes due 2030"},{"label":"Effective","value":"2023-06-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}